Acadia pharm
On March 9, the FDA identified flaws in ACADIA's application for a new drug for Pimavanserin to treat hallucinations and delusions associated with psychosis and dementia.
By April 3, Acadia is likely to receive a full response letter from the FDA.
DRP approval of Pimavanserin is unlikely, but possible.
The stock bounced off 24.00, then 26.00 and 27.00. The figure W is formed
Accumulation for a jump takes 4 days, then a shot.
Risk 1: 5
By April 3, Acadia is likely to receive a full response letter from the FDA.
DRP approval of Pimavanserin is unlikely, but possible.
The stock bounced off 24.00, then 26.00 and 27.00. The figure W is formed
Accumulation for a jump takes 4 days, then a shot.
Risk 1: 5
Хочешь хороших денег – умей выжидать
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.